Global Intracranial Therapeutic 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI04256053

Publication Date:

April 24, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Intracranial Therapeutic market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淚ntracranial Therapeutic Industry Forecast鈥� looks at past sales and reviews total world Intracranial Therapeutic sales in 2024, providing a comprehensive analysis by region and market sector of projected Intracranial Therapeutic sales for 2025 through 2031. With Intracranial Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Intracranial Therapeutic industry.
This Insight Report provides a comprehensive analysis of the global Intracranial Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Intracranial Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Intracranial Therapeutic market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Intracranial Therapeutic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Intracranial Therapeutic.
This report presents a comprehensive overview, market shares, and growth opportunities of Intracranial Therapeutic market by product type, application, key players and key regions and countries.
Segmentation by Type:
Cell-based Therapy
Gene Therapy
Enzyme Replacement Therapy
Segmentation by Application:
Spinal Muscular Atrophy (SMA)
Multiple Sclerosis
Batten Disease
Amyotrophic Lateral Sclerosis
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis AG
BioMarin
CORESTEM Inc.
Alaunos Therapeutics, Inc.
Apic Bio
Stemedica Cell Technologies, Inc.
Voyager Therapeutics
Bayer AG
Abeona Therapeutics
Spark Therapeutics

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Intracranial Therapeutic 麻豆原创 Size (2020-2031)
2.1.2 Intracranial Therapeutic 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Intracranial Therapeutic by Country/Region (2020, 2024 & 2031)
2.2 Intracranial Therapeutic Segment by Type
2.2.1 Cell-based Therapy
2.2.2 Gene Therapy
2.2.3 Enzyme Replacement Therapy
2.3 Intracranial Therapeutic 麻豆原创 Size by Type
2.3.1 Intracranial Therapeutic 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Intracranial Therapeutic 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Intracranial Therapeutic Segment by Application
2.4.1 Spinal Muscular Atrophy (SMA)
2.4.2 Multiple Sclerosis
2.4.3 Batten Disease
2.4.4 Amyotrophic Lateral Sclerosis
2.5 Intracranial Therapeutic 麻豆原创 Size by Application
2.5.1 Intracranial Therapeutic 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Intracranial Therapeutic 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Intracranial Therapeutic 麻豆原创 Size by Player
3.1 Intracranial Therapeutic 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Intracranial Therapeutic Revenue by Player (2020-2025)
3.1.2 Global Intracranial Therapeutic Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Intracranial Therapeutic Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Intracranial Therapeutic by Region
4.1 Intracranial Therapeutic 麻豆原创 Size by Region (2020-2025)
4.2 Global Intracranial Therapeutic Annual Revenue by Country/Region (2020-2025)
4.3 Americas Intracranial Therapeutic 麻豆原创 Size Growth (2020-2025)
4.4 APAC Intracranial Therapeutic 麻豆原创 Size Growth (2020-2025)
4.5 Europe Intracranial Therapeutic 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Intracranial Therapeutic 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Intracranial Therapeutic 麻豆原创 Size by Country (2020-2025)
5.2 Americas Intracranial Therapeutic 麻豆原创 Size by Type (2020-2025)
5.3 Americas Intracranial Therapeutic 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Intracranial Therapeutic 麻豆原创 Size by Region (2020-2025)
6.2 APAC Intracranial Therapeutic 麻豆原创 Size by Type (2020-2025)
6.3 APAC Intracranial Therapeutic 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Intracranial Therapeutic 麻豆原创 Size by Country (2020-2025)
7.2 Europe Intracranial Therapeutic 麻豆原创 Size by Type (2020-2025)
7.3 Europe Intracranial Therapeutic 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Intracranial Therapeutic by Region (2020-2025)
8.2 Middle East & Africa Intracranial Therapeutic 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Intracranial Therapeutic 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Intracranial Therapeutic 麻豆原创 Forecast
10.1 Global Intracranial Therapeutic Forecast by Region (2026-2031)
10.1.1 Global Intracranial Therapeutic Forecast by Region (2026-2031)
10.1.2 Americas Intracranial Therapeutic Forecast
10.1.3 APAC Intracranial Therapeutic Forecast
10.1.4 Europe Intracranial Therapeutic Forecast
10.1.5 Middle East & Africa Intracranial Therapeutic Forecast
10.2 Americas Intracranial Therapeutic Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Intracranial Therapeutic Forecast
10.2.2 Canada 麻豆原创 Intracranial Therapeutic Forecast
10.2.3 Mexico 麻豆原创 Intracranial Therapeutic Forecast
10.2.4 Brazil 麻豆原创 Intracranial Therapeutic Forecast
10.3 APAC Intracranial Therapeutic Forecast by Region (2026-2031)
10.3.1 China Intracranial Therapeutic 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Intracranial Therapeutic Forecast
10.3.3 Korea 麻豆原创 Intracranial Therapeutic Forecast
10.3.4 Southeast Asia 麻豆原创 Intracranial Therapeutic Forecast
10.3.5 India 麻豆原创 Intracranial Therapeutic Forecast
10.3.6 Australia 麻豆原创 Intracranial Therapeutic Forecast
10.4 Europe Intracranial Therapeutic Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Intracranial Therapeutic Forecast
10.4.2 France 麻豆原创 Intracranial Therapeutic Forecast
10.4.3 UK 麻豆原创 Intracranial Therapeutic Forecast
10.4.4 Italy 麻豆原创 Intracranial Therapeutic Forecast
10.4.5 Russia 麻豆原创 Intracranial Therapeutic Forecast
10.5 Middle East & Africa Intracranial Therapeutic Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Intracranial Therapeutic Forecast
10.5.2 South Africa 麻豆原创 Intracranial Therapeutic Forecast
10.5.3 Israel 麻豆原创 Intracranial Therapeutic Forecast
10.5.4 Turkey 麻豆原创 Intracranial Therapeutic Forecast
10.6 Global Intracranial Therapeutic Forecast by Type (2026-2031)
10.7 Global Intracranial Therapeutic Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Intracranial Therapeutic Forecast
11 Key Players Analysis
11.1 Novartis AG
11.1.1 Novartis AG Company Information
11.1.2 Novartis AG Intracranial Therapeutic Product Offered
11.1.3 Novartis AG Intracranial Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Novartis AG Main Business Overview
11.1.5 Novartis AG Latest Developments
11.2 BioMarin
11.2.1 BioMarin Company Information
11.2.2 BioMarin Intracranial Therapeutic Product Offered
11.2.3 BioMarin Intracranial Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 BioMarin Main Business Overview
11.2.5 BioMarin Latest Developments
11.3 CORESTEM Inc.
11.3.1 CORESTEM Inc. Company Information
11.3.2 CORESTEM Inc. Intracranial Therapeutic Product Offered
11.3.3 CORESTEM Inc. Intracranial Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 CORESTEM Inc. Main Business Overview
11.3.5 CORESTEM Inc. Latest Developments
11.4 Alaunos Therapeutics, Inc.
11.4.1 Alaunos Therapeutics, Inc. Company Information
11.4.2 Alaunos Therapeutics, Inc. Intracranial Therapeutic Product Offered
11.4.3 Alaunos Therapeutics, Inc. Intracranial Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Alaunos Therapeutics, Inc. Main Business Overview
11.4.5 Alaunos Therapeutics, Inc. Latest Developments
11.5 Apic Bio
11.5.1 Apic Bio Company Information
11.5.2 Apic Bio Intracranial Therapeutic Product Offered
11.5.3 Apic Bio Intracranial Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Apic Bio Main Business Overview
11.5.5 Apic Bio Latest Developments
11.6 Stemedica Cell Technologies, Inc.
11.6.1 Stemedica Cell Technologies, Inc. Company Information
11.6.2 Stemedica Cell Technologies, Inc. Intracranial Therapeutic Product Offered
11.6.3 Stemedica Cell Technologies, Inc. Intracranial Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Stemedica Cell Technologies, Inc. Main Business Overview
11.6.5 Stemedica Cell Technologies, Inc. Latest Developments
11.7 Voyager Therapeutics
11.7.1 Voyager Therapeutics Company Information
11.7.2 Voyager Therapeutics Intracranial Therapeutic Product Offered
11.7.3 Voyager Therapeutics Intracranial Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Voyager Therapeutics Main Business Overview
11.7.5 Voyager Therapeutics Latest Developments
11.8 Bayer AG
11.8.1 Bayer AG Company Information
11.8.2 Bayer AG Intracranial Therapeutic Product Offered
11.8.3 Bayer AG Intracranial Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Bayer AG Main Business Overview
11.8.5 Bayer AG Latest Developments
11.9 Abeona Therapeutics
11.9.1 Abeona Therapeutics Company Information
11.9.2 Abeona Therapeutics Intracranial Therapeutic Product Offered
11.9.3 Abeona Therapeutics Intracranial Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Abeona Therapeutics Main Business Overview
11.9.5 Abeona Therapeutics Latest Developments
11.10 Spark Therapeutics
11.10.1 Spark Therapeutics Company Information
11.10.2 Spark Therapeutics Intracranial Therapeutic Product Offered
11.10.3 Spark Therapeutics Intracranial Therapeutic Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Spark Therapeutics Main Business Overview
11.10.5 Spark Therapeutics Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.